Publisher: Karger
E-ISSN: 1662-6575|10|2|420-427
ISSN: 1662-6575
Source: Case Reports in Oncology, Vol.10, Iss.2, 2017-05, pp. : 420-427
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Metastatic neuroendocrine tumors (gastrinomas) have a poor prognosis. Octreotide can reduce gastrin levels and alleviate hormonal symptoms, and possibly slow tumor growth as well. No drugs were available except streptozocin for the treatment of metastatic pancreatic neuroendocrine tumor (PNET) in 2008. We report a case of PNET in a 53-year-old woman with multiple liver tumors treated with S-1 plus octreotide. After 6 months from the initiation of the treatment, the pancreatic tumor and liver metastases regressed, and the patient achieved partial response without the development of any serious adverse event. For more than 8 years, the patient has remained asymptomatic without disease progression and is continuing treatment with octreotide and S-1. A marked suppression of gastrin levels has also been achieved. Combination therapy with octreotide and S-1 has been effective and well tolerated in patients with metastatic gastrinoma.
Related content
Pilot Study of Combination Chemotherapy Using Irinotecan plus S-1 for Metastatic Pancreatic Cancer
Oncology, Vol. 75, Iss. 1-2, 2008-08 ,pp. :
Cardiac Recurrence in a Patient with Long-Term Survival from Metastatic Colon Cancer
Case Reports in Oncology, Vol. 5, Iss. 1, 2012-04 ,pp. :